GET DAILY SIGNALSCapsoVision (CV) Sees $9.50 Analyst Target with Potential +41% Upside
Key Takeaways
- The central $9.50 stock price target is the arithmetic mean of two verified, current analyst price targets ($9.00 and $10.00), matching the average reported by several aggregators.
- At a recent verified price near $6.73, reaching $9.50 would require a gain of roughly 41%, a substantial move.
- The verified analyst target range is unusually narrow—$9.00 to $10.00—with ratings clustered at Buy to Strong Buy, reflecting a bullish but concentrated view.
- Supporting factors include an AI-enabled capsule endoscopy pipeline, management guidance for higher second-half 2026 revenue versus the first half, and recent capital raises to fund growth.
- Key risks include persistent net losses, quarterly revenue that has missed estimates, and dilution from an at-the-market (ATM) equity offering of up to $100 million.
- Technical context matters: the stock traded as high as $15.37 (December 2025) and as low as $3.43 (September 2025) over the past year, so the target sits well below the prior peak but far above recent lows.
Understanding the Analyst Consensus for CV
CapsoVision, Inc. (CV) is a commercial-stage medical technology company based in Saratoga, California, focused on capsule endoscopy and AI-enabled imaging for the gastrointestinal tract. Its products include the CapsoCam Plus single-use capsule, CapsoCam Colon, and cloud-based viewing software such as CapsoCloud and CapsoView.
The central $9.50 figure is the arithmetic mean of two verified, current analyst price targets. Roth MKM analyst Kevin Holder maintained a Buy rating with a $9.00 target in September 2026, while a second firm carries a $10.00 target. That produces a range of $9.00 to $10.00 and a mean of $9.50. Some data providers list up to four analysts, but the distinct, dated targets cluster in this narrow band. The consensus is generally described as Moderate Buy to Strong Buy.
The reasoning behind the targets is consistent: analysts see upside from a growing capsule endoscopy franchise, new product launches, and AI-driven software, offset by early-stage revenue and ongoing losses. Notably, Roth Capital previously raised its target to $11 from $7 in March 2026 following a fourth-quarter pre-announcement and a $14 million private placement, before settling at $9.00 later in the year—illustrating how quickly assumptions around dilution and cash burn can shift. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the shares recently trading near $6.73, a move to $9.50 implies roughly 41% upside—a substantial advance for a small-cap medical device name. The path would most likely depend on sustained revenue acceleration, improving gross margins, and evidence that new AI and colon capsule products are gaining commercial traction.
Fundamentals remain early-stage. In its most recent quarter, the company posted an EPS loss of about $0.15, slightly wider than the $0.13 loss analysts expected, on revenue near $3.64 million versus a roughly $3.81 million estimate. Management has, however, guided for higher revenue in the second half of 2026 than the first half, which underpins the bullish case if execution follows through.
Factors That Could Support a Move Toward the Target
- AI-enabled product expansion: The company is advancing AI capabilities and colon-focused capsule programs, which could broaden its addressable market beyond small-bowel imaging.
- Second-half revenue guidance: The expectation of stronger H2 2026 revenue than H1 provides a near-term catalyst if delivered.
- Funding runway: A $14 million private placement and an ATM facility of up to $100 million give the company capital for R&D, sales, and marketing.
- Favorable demographic tailwinds: Demand for minimally invasive GI diagnostics and screening continues to grow, supporting the long-term market outlook.
Risks That Could Prevent the Target From Being Reached
- Persistent losses: The company remains unprofitable, with negative EBITDA and a recent EPS miss.
- Dilution risk: An up-to-$100 million ATM offering can pressure the share price as new stock is issued.
- Competition: Capsule endoscopy is a competitive field with larger, well-funded rivals.
- Small-cap volatility: The shares have swung from $3.43 to $15.37 within a year, and the company was recently removed from several Russell value and small-cap indexes, which can reduce passive demand.
Technical Levels and Market Structure
The 52-week range spans $3.43 to $15.37. At roughly $6.73, the stock trades well below its December 2025 peak but above its post-IPO low. The $9.50 target sits roughly midway between those extremes and just below the psychological $10.00 level. Durable resistance appears near the prior $15.37 high, while support has formed in the mid-to-high $5 range in recent months. A sustained move back above $10 would be an important structural signal for the bullish case.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, and the two targets here appear consistent with that convention. Key items to watch include quarterly earnings and guidance updates, progress on the ATM offering and its dilutive effect, analyst revisions to revenue-growth and margin assumptions, new product and AI milestones, and any changes in the competitive landscape for capsule endoscopy. Interest-rate and small-cap sentiment shifts can also influence a stock with this risk profile. From what I see, monitoring these elements closely helps put the $9.50 target in proper context.
Final Assessment
The $9.50 target is a genuine, verifiable analyst-derived figure—the average of two current targets ($9.00 and $10.00)—but it rests on a narrow and concentrated sample. Reaching it would require a substantial advance of roughly 41% from recent levels, driven by successful execution on AI-enabled products and second-half revenue growth. Set against that are real obstacles: ongoing losses, modest revenue that has missed estimates, and meaningful dilution risk from the ATM offering. The outcome depends less on a single catalyst and more on whether CapsoVision (CV) can convert its capital and product pipeline into accelerating, durable revenue growth. No analyst target, including the $9.50 mean, is a guarantee.
Exploring AI Daily Buy/Sell Signals for Additional Perspective
In my research process, I sometimes reference Tickeron’s AI Daily Buy/Sell Signals to get a sense of how automated analysis aligns with fundamental views on names like CV. The tool monitors thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. It offers one structured way to supplement ongoing fundamental work without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CV in downward trend: price dove below 50-day moving average on November 05, 2026
CV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 13 of 15 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CV as a result. In 19 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for CV turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 5 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CV advanced for three days, in 63 of 73 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 31 of 34 cases where CV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CV's P/B Ratio (25.542) is slightly higher than the industry average of (4.142). P/E Ratio (-5.672) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (21.598) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement